Retts, West and Dravet syndromes. Devastating juvenile epilepsy disorders.
Dr French just finished her work on the Novartis trial.
'"I have to emphasize to you what a big leap this is," Jacqueline French, MD, professor, neurology and co-director, epilepsy research and epilepsy clinical trials, NYU Comprehensive Epilepsy Center, New York, told Medscape Medical News.
"Up until now, we have not treated anybody for their epilepsy; we have only treated them for their seizures. We have given them drugs that suppress their seizures, but we have not fundamentally changed the mechanism underlying that, which caused the epilepsy."' http://www.medscape.com/viewarticle/862306
What could be next?
"I am extremely impressed with the positive preclinical epilepsy data for ANAVEX 2-73, which demonstrates a significant reduction in anti-seizure efficacy relative to three currently approved epilepsy drugs as well as significant synergy with each of these drugs. Additionally, ANAVEX 2-73 was shown to be safe in a Phase 1 human trial, which is critical to next-general epilepsy therapies,” said Dr. French. “I look forward to collaborating with Anavex and its impressive team of scientific advisors as we work to further develop ANAVEX 2-73." http://www.anavex.com/?news=anavex-appoints-epilepsy-and-clinical-trial-methodology-expert-to-scientific-advisory-board §
News 
Market Data 
Discover 
AI
